Comprehensive Stock Comparison
Compare The Oncology Institute, Inc. (TOI) vs Concord Medical Services Holdings Limited (CCM) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | TOI | 21.3% revenue growth vs CCM's -28.6% |
| Quality / Margins | TOI | -14.4% net margin vs CCM's -44.6% |
| Stability / Safety | CCM | Beta 0.25 vs TOI's 1.56, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | TOI | +239.2% vs CCM's -29.9% |
| Efficiency (ROA) | CCM | -2.4% ROA vs TOI's -40.5%, ROIC -7.7% vs -40.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
The Oncology Institute operates a network of outpatient cancer care clinics providing comprehensive oncology services including chemotherapy, radiation, and clinical trial management. It generates revenue primarily from fee-for-service medical oncology treatments — with infusion services and physician consultations being major contributors — supplemented by clinical trial management fees. The company's competitive advantage lies in its integrated care model that combines clinical services with research capabilities across its 67 clinic locations, creating a scalable platform for community-based cancer care.
Concord Medical Services operates a network of radiotherapy and diagnostic imaging centers across China, specializing in cancer treatment services. It generates revenue primarily from operating its network of treatment centers — including linear accelerators and gamma knife systems — and from hospital management services, with additional income from equipment leasing and medical IT services. The company's competitive advantage lies in its established network of specialized cancer treatment facilities across China and its expertise in advanced radiotherapy technologies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
TOI leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). CCM leads in 1 (Profitability & Efficiency). 1 tied.
Financial Metrics (TTM)
TOI and CCM operate at a comparable scale, with $461M and $366M in trailing revenue. TOI is the more profitable business, keeping -14.4% of every revenue dollar as net income compared to CCM's -44.6%. On growth, TOI holds the edge at +36.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TOIThe Oncology Inst… | CCMConcord Medical S… |
|---|---|---|
| RevenueTrailing 12 months | $461M | $366M |
| EBITDAEarnings before interest/tax | -$34M | -$359M |
| Net IncomeAfter-tax profit | -$66M | -$163M |
| Free Cash FlowCash after capex | -$28M | $0 |
| Gross MarginGross profit ÷ Revenue | +14.8% | -11.4% |
| Operating MarginEBIT ÷ Revenue | -8.9% | -131.0% |
| Net MarginNet income ÷ Revenue | -14.4% | -44.6% |
| FCF MarginFCF ÷ Revenue | -6.0% | -2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +36.7% | -8.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +22.2% | +84.0% |
Valuation Metrics
| Metric | TOIThe Oncology Inst… | CCMConcord Medical S… |
|---|---|---|
| Market CapShares × price | $219M | $167M |
| Enterprise ValueMkt cap + debt − cash | $292M | $708M |
| Trailing P/EPrice ÷ TTM EPS | -4.07x | -0.01x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 0.87x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.56x | 2.98x |
| Price / BookPrice ÷ Book value/share | 60.43x | 0.00x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CCM delivers a -9.5% return on equity — every $100 of shareholder capital generates $-9 in annual profit, vs $-2 for TOI. CCM carries lower financial leverage with a 2.43x debt-to-equity ratio, signaling a more conservative balance sheet compared to TOI's 34.31x.
| Metric | TOIThe Oncology Inst… | CCMConcord Medical S… |
|---|---|---|
| ROE (TTM)Return on equity | -2.1% | -9.5% |
| ROA (TTM)Return on assets | -40.5% | -2.4% |
| ROICReturn on invested capital | -40.9% | -7.7% |
| ROCEReturn on capital employed | -40.8% | -12.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | 34.31x | 2.43x |
| Net DebtTotal debt minus cash | $73M | $3.7B |
| Cash & Equiv.Liquid assets | $50M | $216M |
| Total DebtShort + long-term debt | $123M | $3.9B |
| Interest CoverageEBIT ÷ Interest expense | -4.92x | -2.40x |
Total Returns (with DRIP)
A $10,000 investment in TOI five years ago would be worth $2,651 today (with dividends reinvested), compared to $992 for CCM. Over the past 12 months, TOI leads with a +239.2% total return vs CCM's -29.9%. The 3-year compound annual growth rate (CAGR) favors TOI at 27.0% vs CCM's -36.5% — a key indicator of consistent wealth creation.
| Metric | TOIThe Oncology Inst… | CCMConcord Medical S… |
|---|---|---|
| YTD ReturnYear-to-date | -21.3% | -14.8% |
| 1-Year ReturnPast 12 months | +239.2% | -29.9% |
| 3-Year ReturnCumulative with dividends | +105.0% | -74.4% |
| 5-Year ReturnCumulative with dividends | -73.5% | -90.1% |
| 10-Year ReturnCumulative with dividends | -70.2% | -92.1% |
| CAGR (3Y)Annualised 3-year return | +27.0% | -36.5% |
Risk & Volatility
CCM is the less volatile stock with a 0.25 beta — it tends to amplify market swings less than TOI's 1.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TOI currently trades 59.2% from its 52-week high vs CCM's 33.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TOIThe Oncology Inst… | CCMConcord Medical S… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.56x | 0.25x |
| 52-Week HighHighest price in past year | $4.88 | $10.77 |
| 52-Week LowLowest price in past year | $0.60 | $3.18 |
| % of 52W HighCurrent price vs 52-week peak | +59.2% | +33.8% |
| RSI (14)Momentum oscillator 0–100 | 55.5 | 41.9 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 7K |
Analyst Outlook
Wall Street rates TOI as "Buy" and CCM as "Buy".
| Metric | TOIThe Oncology Inst… | CCMConcord Medical S… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $5.00 | — |
| # AnalystsCovering analysts | 3 | 2 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jun 20 | Feb 26 | Change |
|---|---|---|---|
| The Oncology Instit… (TOI) | 100 | 27.63 | -72.4% |
| Concord Medical Ser… (CCM) | 100 | 23.64 | -76.4% |
The Oncology Instit… (TOI) returned -73% over 5 years vs Concord Medical Ser… (CCM)'s -90%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| The Oncology Instit… (TOI) | $155M | $393M | +153.2% |
| Concord Medical Ser… (CCM) | $616M | $384M | -37.7% |
Concord Medical Services Holdings Limited's revenue grew from $616M (2015) to $384M (2024) — a -5.1% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| The Oncology Instit… (TOI) | -2.6% | -16.4% | -535.2% |
| Concord Medical Ser… (CCM) | -12.7% | -80.3% | -532.0% |
Concord Medical Services Holdings Limited's net margin went from -13% (2015) to -80% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| The Oncology Instit… (TOI) | -0.06 | -0.71 | -1037.8% |
| Concord Medical Ser… (CCM) | -523.8 | -2,116.8 | -304.1% |
Concord Medical Services Holdings Limited's EPS grew from $-523.80 (2015) to $-2116.80 (2024).
Chart 5Free Cash Flow — 5 Years
The Oncology Institute, Inc. generated $-30M FCF in 2024 (+15% vs 2021). Concord Medical Services Holdings Limited generated $-809M FCF in 2024 (+28% vs 2021).
TOI vs CCM: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is TOI or CCM a better buy right now?
Analysts rate The Oncology Institute, Inc. (TOI) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TOI or CCM?
Over the past 5 years, The Oncology Institute, Inc. (TOI) delivered a total return of -73.5%, compared to -90.1% for Concord Medical Services Holdings Limited (CCM). A $10,000 investment in TOI five years ago would be worth approximately $3K today (assuming dividends reinvested). Over 10 years, the gap is even starker: TOI returned -70.2% versus CCM's -92.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TOI or CCM?
By beta (market sensitivity over 5 years), Concord Medical Services Holdings Limited (CCM) is the lower-risk stock at 0.25β versus The Oncology Institute, Inc.'s 1.56β — meaning TOI is approximately 526% more volatile than CCM relative to the S&P 500. On balance sheet safety, Concord Medical Services Holdings Limited (CCM) carries a lower debt/equity ratio of 2% versus 34% for The Oncology Institute, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — TOI or CCM?
The Oncology Institute, Inc. (TOI) is the more profitable company, earning -16.4% net margin versus -80.3% for Concord Medical Services Holdings Limited — meaning it keeps -16.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TOI leads at -15.3% versus -138.6% for CCM. At the gross margin level — before operating expenses — TOI leads at 13.7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — TOI or CCM?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is TOI or CCM better for a retirement portfolio?
For long-horizon retirement investors, Concord Medical Services Holdings Limited (CCM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.25)). The Oncology Institute, Inc. (TOI) carries a higher beta of 1.56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CCM: -92.1%, TOI: -70.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between TOI and CCM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.